The PARP inhibitor olaparib induces CD8+ T cell infiltration and activation in vivo through activation of the cGAS/STING pathway in tumor cells with paracrine activation of dendritic cells and was more significant in HR-deficient than in HR-proficient breast cancer cells [43]. The gene discussed is PARP1; the disease is neoplasm.